2024 Investorideas.com report predicts 18% CAGR for pancreatic cancer market, reaching $36bn by 2036, with Oncolytics Biotech® Inc.

2024 report by Investorideas.com highlights pancreatic cancer market growth, driven by a CAGR of ~18% from 2024-2036 and a revenue of USD 36bn by 2036 (up from USD 6bn in 2023). Oncolytics Biotech® Inc., a clinical-stage immunotherapeutics company focusing on oncology, is among the featured companies in this sector. The American Cancer Society projects 66,440 pancreatic cancer diagnoses in the US in 2024.